The Gosselies, Belgium-based bone cell company focuses on innovations in orthopedics and bone diseases.
Dr. Theoharis has more than 15 years of experience in mergers and acquisitions as well as research and development in the pharma and biotech industry.
He will lead Bone Therapeutics’ corporate development activities, spearhead business strategy and advance the company’s commercial strategies.
Dr. Theoharis will also guide Bone Therapeutics’ business initiatives as it looks to advance its product pipeline through clinical development.
More articles on biologics:
6 industry layoffs, furloughs for physician leaders to know
Dr. Neal ElAttrache defends orthopedic surgeries performed during COVID-19 crisis
‘The patients are deferred; they’re not going away,’ says Life Spine CEO on coronavirus
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
